CuRNA, Inc.
2 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
Previously recorded as Opko Curna, LLC (to 2012)
27
Ending by 2030
Aug 2029
Next term end
When these terms end
Held patents by the year their term ends
20262027202820292030203120322033203420352036203720382039204020412042204320442045
Fee deadlines
Maintenance fees fall due 3.5, 7.5 and 11.5 years after grant. A missed fee ends a patent at the end of the six month grace period that follows, not on the due date.
- 4 fees due Dec 2 to 30, 2026 · next Dec 2
- 7 fees due Jan 2 to 28, 2027 · next Jan 2
- 1 fee due Feb 6, 2027The maintenance fee for Treatment of Collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene (US 10,370,657) comes due Feb 6, 2027. Unpaid by Aug 6, 2027, it lapses early.
- 1 fee due Mar 15, 2027The maintenance fee for Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene (US 9,133,456) comes due Mar 15, 2027. Unpaid by Sep 15, 2027, it lapses early.
- 4 fees due Apr 8 to 22, 2027 · next Apr 8
- 2 fees due May 3 to 5, 2027 · next May 3
- 3 fees due Jun 1 to 30, 2027 · next Jun 1
- 1 fee due Aug 23, 2027The maintenance fee for Treatment of pancreatic developmental gene related diseases by inhibition of natural antisense transcript to a pancreatic developmental gene (US 9,267,136) comes due Aug 23, 2027. Unpaid by Feb 23, 2028, it lapses early.
- 2 fees due Sep 10 to 30, 2027 · next Sep 10
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
Patents held now
Soonest term end first. Each date below is computed on that patent's own page, which shows the rule, the adjustments and the fee history it was derived from.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,133,456 | Treatment of antiviral gene related diseases by inhibition of natural antisense transcript to an antiviral gene In force · From the USPTO record | In force | From the USPTO record | |
| US 8,153,606 | Treatment of apolipoprotein-A1 related diseases by inhibition of natural antisense transcript to apolipoprotein-A1 In force · From the USPTO record | In force | From the USPTO record | |
| US 8,921,329 | Treatment of Erythropoietin (EPO) Related Diseases by Inhibition of Natural Antisense Transcript to Epo In force · High confidence | In force | High confidence | |
| US 10,358,645 | Treatment of erythropoietin (EPO) related diseases by inhibition of natural antisense transcript to EPO In force · From the USPTO record | In force | From the USPTO record | |
| US 10,358,646 | Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene In force · From the USPTO record | In force | From the USPTO record | |
| US 11,697,814 | Treatment of tumor suppressor gene related diseases by inhibition of natural antisense transcript to the gene In force · From the USPTO record | In force | From the USPTO record | |
| US 10,519,448 | Treatment of brain derived neurotrophic factor (BDNF) related diseases by inhibition of natural antisense transcript to BDNF In force · From the USPTO record | In force | From the USPTO record | |
| US 10,465,192 | Treatment of delta-like 1 homolog (DLK1) related diseases by inhibition of natural antisense transcript to DLK1 In force · From the USPTO record | In force | From the USPTO record | |
| US 9,163,285 | Treatment of tristetraproline (TTP) related diseases by inhibition of natural antisense transcript to TTP In force · From the USPTO record | In force | From the USPTO record | |
| US 10,604,755 | Treatment of lipid transport and metabolism gene related diseases by inhibition of natural antisense transcript to a lipid transport and metabolism gene In force · From the USPTO record | In force | From the USPTO record |
Also on record, not counted in the 51: 2 patents in force now held by others · 59 lapsed for an unpaid fee · 1 past the fee grace period. List them
Sources and methods
Compiled from the USPTO record, grants, published applications and recorded assignments, not yet reviewed by hand.
How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
Published applications
US patent applications published under this name that have not become patents. An application is published about eighteen months after its earliest filing; one that has not been published is in no public record.
2 abandoned · 12 no status recorded